Benoit Bensaid
Overview
Explore the profile of Benoit Bensaid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ingen-Housz-Oro S, Guichard E, Milpied B, Bensaid B, Collet E, Barbaud A, et al.
J Am Acad Dermatol
. 2024 May;
91(3):544-547.
PMID: 38754628
No abstract available.
2.
Bruggen M, Walsh S, Ameri M, Anasiewicz N, Maverakis E, French L, et al.
JAMA Dermatol
. 2023 Nov;
160(1):37-44.
PMID: 37966824
Importance: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment...
3.
Ingen-Housz-Oro S, Milpied B, Bensaid B, Elshot Y, Bruggen M, Starace M, et al.
Melanoma Res
. 2023 Feb;
33(2):155-158.
PMID: 36749114
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely reported. The objective of this study is to...
4.
Kridin K, Bruggen M, Walsh S, Bensaid B, Ranki A, Oppel E, et al.
J Eur Acad Dermatol Venereol
. 2022 Dec;
37(4):753-762.
PMID: 36479739
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. Objective: To explore treatment approaches across Europe and their impact on the...
5.
Ingen-Housz-Oro S, Milpied B, Badrignans M, Carrera C, Elshot Y, Bensaid B, et al.
Melanoma Res
. 2022 Apr;
32(3):205-210.
PMID: 35377864
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), bullous life-threatening reactions are rare. To better define the clinical and histological features, treatment, and prognosis of ICI-related severe blistering...
6.
Guerrois F, Thibault C, Lheure C, Sohier P, Bensaid B, Ingen-Housz-Oro S, et al.
Eur J Cancer
. 2022 Mar;
167:168-171.
PMID: 35346550
No abstract available.
7.
Villani A, Rozieres A, Bensaid B, Eriksson K, Mosnier A, Albert F, et al.
Sci Adv
. 2021 Mar;
7(12).
PMID: 33741590
Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction. To better understand why skin symptoms are so severe, we conducted a prospective immunophenotyping study on skin and blood....
8.
Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, Jachiet M, et al.
J Allergy Clin Immunol Pract
. 2020 Jun;
8(8):2777-2779.e1.
PMID: 32525093
No abstract available.
9.
Garel B, Ingen-Housz-Oro S, Afriat D, Prost-Squarcioni C, Tetart F, Bensaid B, et al.
Br J Clin Pharmacol
. 2018 Dec;
85(3):570-579.
PMID: 30511379
Aims: Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted...
10.
Ingen-Housz-Oro S, Duong T, Bensaid B, Bellon N, de Prost N, Lu D, et al.
Orphanet J Rare Dis
. 2018 Apr;
13(1):56.
PMID: 29636107
Epidermal necrolysis (EN) encompasses Stevens-Johnson syndrome (SJS, < 10% of the skin affected), Lyell syndrome (toxic epidermal necrolysis, TEN, with ≥30% of the skin affected) and an overlap syndrome (10...